INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
Market Wire, November, 2007
For further information, please contact: Dan Suesskind, Teva Pharmaceutical Industries Ltd. 972-2-941-1717 Chief Financial Officer George Barrett, Corp. E. V.P. - Global Teva Pharmaceutical Industries Ltd. (215) 591-3030 pharmaceutical Markets Chief Executive Officer Teva North America Liraz Kalif / Teva Pharmaceutical Industries Ltd. 972-3-926-7281 Kevin Mannix, Teva North America (215) 591-8912 Investor Relations Sven Andréasson Active Biotech 46 46 19 20 49 President & CEO Tomas Leanderson Active Biotech 46 46 19 20 95 Chief Scientific Officer Cecilia Hofvander Active Biotech 46 46 19 11 22 Manager Corporate Communication
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY -- http://hugin.info/1002/R/1166589/228490.pdf
Copyright © Hugin ASA 2007. All rights reserved.
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics


